- Home
- Companies
- usa massachusetts
- tumor microenvironment
Show results for
Refine by
Tumor Microenvironment Suppliers Serving Massachusetts
40 companies found
based inKöln, GERMANY
Singleron Biotechnologies is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques in clinical diagnosis, drug development, and health management. Singleron Biotechnologies is an innovative ...
GEXSCOPE Single Cell V(D)J Kit enables simultaneous detection of T-cell or B-cell receptor gene expression, together with whole transcriptome expression at single-cell ...
based inSeattle, WASHINGTON (USA)
As the pioneer in the field of spatial biology, NanoString enables scientists across the globe to envision molecular interactions in three dimensions with three different systems, the nCounter Analysis System, the GeoMx Digital Spatial Profiler ...
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for novel small molecule PD-L1 ...
based inMinneapolis, MINNESOTA (USA)
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services. Science ...
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
During the tumor formation process, cancer cells release various cytokines and growth factors into the surroundings and reprogram many other types of cells to establish a tumor microenvironment. As ...
based inCounty of New Castle, DELAWARE (USA)
MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...
A comprehensive suite of bioinformatics services for NGS data analysis encompassing a wide range of applications including genomics, transcriptomics, single cell genomics, immune profiling, genome assembly and annotation and more. Our team of ...
based inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce ...
based inDurham, NORTH CAROLINA (USA)
Cancer is the second leading cause of death in the U.S. and metastatic disease remains predominantly incurable. New cancer cases and healthcare costs continue to increase year-over-year. Precision medicine aims to select the most effective ...
Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, ...
based inBasel, SWITZERLAND
We at Auris Medical are a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. We are focusing on the development of intranasal betahistine ...
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene ...
based inSan Francisco, CALIFORNIA (USA)
Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. A key application is Prellis’ Externalized Immune System, EXIS, which through the creation of lymph node ...
EXIS Human Immune Response: Prellis utilizes its proprietary holographic printing technology to engineer 3D printed lymph node organoids (LNOs) that recreates the human immunobiology in vitro allowing direct access to a fully functional human immune ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and another domain that binds to an extracellular molecule from tumoral microenvironment. ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Four transgenes: Producing an anti-FAP bispecific plus cytokines/chemokines. Currently in clinical trials in the US and UK. See our clinical trials page for more information. The aim of this study is to characterise the safety, tolerability and ...
based inDurham, NORTH CAROLINA (USA)
GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our ...
based inSan Francisco, CALIFORNIA (USA)
Cypre is a biotechnology company dedicated to overcoming therapeutic resistance for cancer patients. Our 3D Tumor Model Platform engineers the tumor microenvironment in vitro at high throughput for drug efficacy and MOA studies. We are now applying ...
based inSan Diego, CALIFORNIA (USA)
Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments. We are pioneers in using the latest ...